Skip to main content

Advertisement

SpringerLink
Log in

At the frontiers of lung fibrosis therapy

  • News Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Despite recent failures, a flurry of activity in biotech and pharma is raising hopes that an effective drug for this fatal lung disease is on the way. Ken Garber investigates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: In IPF, the normal wound healing response goes fatally wrong, as resident fibroblasts become collagen-secreting myofibroblasts that cause continuous scar formation in the lung.

Katie Vicari

References

  1. Noble, P.W. et al. Lancet 377, 1760–1769 (2011).

    Article  CAS  Google Scholar 

  2. Raghu, G. et al. Am. J. Respir. Crit. Care Med. 183, 788–824 (2011).

    Article  Google Scholar 

  3. Barry-Hamilton, V. et al. Nat. Med. 16, 1009–1017 (2010).

    Article  CAS  Google Scholar 

  4. Tager, A.M. et al. Nat. Med. 14, 45–54 (2008).

    Article  CAS  Google Scholar 

  5. Richeldi, L. et al. N. Engl. J. Med. 365, 1079–1087 (2011).

    Article  CAS  Google Scholar 

  6. Maher, T.M. Eur. Respir. Rev. 22, 148–152 (2013).

    Article  Google Scholar 

  7. Idiopathic Pulmonary Fibrosis Clinical Research Network. N. Engl. J. Med. 366, 1968–1977 (2012).

  8. Van Den Blink, B. et al. American Thoracic Society meeting abstract A5707 (2013).

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

At the frontiers of lung fibrosis therapy. Nat Biotechnol 31, 781–783 (2013). https://doi.org/10.1038/nbt.2687

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2687

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation